KP Biomedical Engineering - Issue #19

-Bausch + Lomb to Participate in the 43rd Annual J.P. Morgan Healthcare Conference VAUGHAN, Ontario--(BUSINESS WIRE)

--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Chief Financial Officer Sam Eldessouky and Chief Medical Officer and Head of Research & Development Yehia Hashad, M.D., will participate in a company presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025

-Exact Sciences to Participate in J.P. Morgan Healthcare Conference MADISON, Wis.--(BUSINESS WIRE)

--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, announced that company management will participate in the following conference and invited investors to participate by webcast. J.P. Morgan Healthcare Conference, San Francisco Presentation followed by Q&A on Monday, January 13, 2025 at 1:30 p.m. ET

-Align Technology to Announce Fourth Quarter and 2024 Results on February 5, 2025 TEMPE, Ariz.--(BUSINESS WIRE)

--Align Technology, Inc. (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign? System of clear aligners, iTero? intraoral scanners, and exocad? CAD/CAM software for digital orthodontics and restorative dentistry, announced that it will report fourth quarter and 2024 financial results on Wednesday, February 5, 2025, after the close of market. Financial results will be released at 4:00 p.m. ET (2:00 p.m. MT)

-Cardiac Arrhythmia Monitoring Device Market Report and Company Analysis 2024-2032 Featuring Abbott, GE, Medtronic, and Boston Scientific Among Others - ResearchAndMarkets.com DUBLIN--(BUSINESS WIRE)

--The "Cardiac Arrhythmia Monitoring Device Market Report By Application, Type, End User, Countries and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering. Cardiac Arrhythmia Monitoring Device Market is expected to be US$ 11.55 billion by 2032 from US$ 6.21 billion in 2023, with a CAGR of 7.14% during 2024 to 2032.

-China Diabetes Device Market Forecast Report and Company Analysis 2024-2032 Featuring Roche, Abbott Laboratories, Novo Nordisk A/S, BD, Medtronic, Eli Lilly, Sanofi - ResearchAndMarkets.com DUBLIN--(BUSINESS WIRE)

--The "China Diabetes Device Market Forecast Report by Types, Distribution Channel and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering. The China Diabetes Device market is expected to reach US$ 6.22 Billion in 2023 to US$ 12.74 Billion by 2032, with a CAGR of 8.30 % from 2024 to 2032 Recent decades have seen a sharp increase in the prevalence of diabetes in China, which presents a serious public health concern for the country.

-CONMED Corporation to Present at the J.P. Morgan Healthcare Conference LARGO, Fla.--(BUSINESS WIRE)

--CONMED Corporation (NYSE: CNMD) announced that Patrick J. Beyer, President and Chief Executive Officer, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the J.P. Morgan Healthcare Conference at 4:30 p.m. PT (7:30 p.m. ET) on Monday, January 13, 2025 in San Francisco, CA.

-Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 10, 2025 CINCINNATI--(BUSINESS WIRE)

--Medpace Holdings, Inc. (Nasdaq: MEDP) (“Medpace”) announced that it will report its fourth quarter and fiscal year 2024 financial results after the market close on Monday, February 10, 2025. The Company will host a conference call the following morning, Tuesday, February 11, 2025, at 9:00 a.m. ET to discuss these results.

-$1.95 Bn Medical Overmolding Market Trends, Opportunities and Forecast to 2030 - ResearchAndMarkets.com DUBLIN--(BUSINESS WIRE)

--The "Medical Overmolding Market: Market Size, Trends, Opportunities and Forecast by Application, End-User Type, Overmold Material Type, Region, By Country: 2020-2030" report has been added to ResearchAndMarkets.com's offering. Global Medical Overmolding Market was valued at USD 1.95 billion and is expected to grow at a CAGR of 4.3% during 2025-2030.

-Strategic Expansion Extends Fusion Orthopedics’ Reach in Foot & Ankle MESA, Ariz.--(BUSINESS WIRE)

--Fusion Orthopedics USA, LLC (“Fusion”) announced that it has expanded its robust product portfolio with the addition of the Metalogix External Fixation Systems. A seamless transition of Metalogix’s operations, distribution, and hospital accounts to Fusion is already substantially complete.

-Worldwide Wearables First as Novosound Demonstrates Ultrasound Blood Pressure Monitoring at CES 2025 GLASGOW, Scotland--(BUSINESS WIRE)

--In what will be a worldwide wearable first, Novosound is set to demonstrate ultrasound blood pressure monitoring at CES 2025 in Las Vegas between 7th-10th January, with the company revealing how it has been able to achieve accuracy levels comparable to conventional electronic cuff devices via the miniaturization of its innovative technology in wearable devices.

-Smartphone app enhances retention and reduces opioid use in patients

--Patients with opioid use disorder can reduce their days of opioid use and stay in treatment longer when using a smartphone app as supportive therapy in combination with medication, a new study by The University of Texas Health Science Center at San Antonio (UT Health San Antonio) shows.

-Machine learning reveals how metabolite profiles predict aging and health

--Researchers developed metabolomic aging clocks using machine learning, uncovering links between metabolite profiles, health outcomes, and lifespan.

-AI-driven surveillance system to combat emerging infectious diseases

--Researchers have come up with a new way to identify more infectious variants of viruses or bacteria that start spreading in humans - including those causing flu, COVID, whooping cough and tuberculosis.

-AI-based models can outperform human experts at identifying ovarian cancer

--A new international study led by researchers at Karolinska Institutet in Sweden shows that AI-based models can outperform human experts at identifying ovarian cancer in ultrasound images.

-Research explores how carbon nanotubes help remove steroid hormones from water

--Steroid hormones are among the most widespread aquatic micropollutants. They are harmful to human health, and they cause ecological imbalances in aquatic environments.

-New AI techniques improve tumor detection in PET and CT scans

--Artificial intelligence has the potential to improve the analysis of medical image data. For example, algorithms based on deep learning can determine the location and size of tumors.

-New artificial muscle mimics natural tissue with high elasticity and toughness

--The study, led by Dr. Cheng-Hui Li from the School of Chemistry and Chemical Engineering, Nanjing University, and Dr. Pengfei Zheng from the Children's Hospital of Nanjing Medical University, successfully developed an artificial muscle with mechanical properties similar to natural muscle tissue.

-New nanopore-based tool enables single molecule disease detection

--UC Riverside scientists have developed a nanopore-based tool that could help diagnose illnesses much faster and with greater precision than current tests allow, by capturing signals from individual molecules.

-Polarimetry tracks Achilles tendon regeneration

--Achilles tendon injuries are common but challenging to monitor during recovery due to the limitations of current imaging techniques. Researchers, led by Associate Professor Zeng Nan from the International Graduate School at Shenzhen, Tsinghua University, have applied Mueller matrix polarimetry, a non-invasive imaging method, to more accurately observe and evaluate the healing of Achilles tendon injuries.

-Clue's CEO Rhiannon White on the Future of Femtech and PCOS

--Under Rhiannon White's leadership, Clue is transforming menstrual health tracking into a powerful tool for research and improved reproductive health outcomes.

-Rice researchers develop new construction kit for engineering smart cells

Rice University bioengineers have developed a new construction kit for building custom sense-and-respond circuits in human cells.

-Advanced imaging technology detects undiagnosed metastases in high-risk prostate cancer

--A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than previously thought.